These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 37101896)

  • 41. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TEAD Inhibitors Sensitize KRAS
    Tammaccaro SL; Prigent P; Le Bail JC; Dos-Santos O; Dassencourt L; Eskandar M; Buzy A; Venier O; Guillemot JC; Veeranagouda Y; Didier M; Spanakis E; Kanno T; Cesaroni M; Mathieu S; Canard L; Casse A; Windenberger F; Calvet L; Noblet L; Sidhu S; Debussche L; Moll J; Valtingojer I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sotorasib Edges Closer to Approval.
    Cancer Discov; 2021 May; 11(5):OF2. PubMed ID: 33547148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.
    O'Sullivan É; Keogh A; Henderson B; Finn SP; Gray SG; Gately K
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glimmers of hope for targeting oncogenic KRAS-G12D.
    Tang D; Kang R
    Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with
    Zhou KI; Lin C; Tseng CL; Ramnath N; Dowell JE; Kelley MJ
    JTO Clin Res Rep; 2024 May; 5(5):100670. PubMed ID: 38746048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes following KRAS
    Chen QA; Lin WH; Zhou XX; Cao Z; Feng XL; Gao YB; He J
    Pharmacol Res; 2024 Feb; 200():107060. PubMed ID: 38185210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
    Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
    J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ
    Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Target Therapy Hyperbole: "KRAS (p.G12C)"-The Simplification of a Complex Biological Problem.
    Chetta M; Basile A; Tarsitano M; Rivieccio M; Oro M; Capitanio N; Bukvic N; Priolo M; Rosati A
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC).
    Johnson M; Younan D; Kent ST; Mesa-Frias M; Alan Brookhart M; Balasubramanian A; Spira A
    Lung Cancer; 2024 Nov; 197():107960. PubMed ID: 39369609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
    Karachaliou A; Kotteas E; Fiste O; Syrigos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting
    Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
    Front Oncol; 2022; 12():796832. PubMed ID: 35251972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
    Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
    Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct Targeting
    Reita D; Pabst L; Pencreach E; Guérin E; Dano L; Rimelen V; Voegeli AC; Vallat L; Mascaux C; Beau-Faller M
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
    Cekani E; Epistolio S; Dazio G; Cefalì M; Wannesson L; Frattini M; Froesch P
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.